Alluvi, formerly BI 4744, represents a notable development in obesity therapy. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable results in https://sociallytraffic.com/story7191299/alluvi-a-detailed-investigation-into-the-medication-s-prospects